Interventional Glaucoma

Latanoprostene bunod especially useful to patients who do not respond to first-line therapy

Novel platforms address adherence; clinicians look to efficacy, treatment duration

Here is one question to help clinicians decide: ‘What is the anatomy giving me?’

Exploring broad utility of netarsudil for ROCK inhibition across spectrum of glaucoma

Research to understand underlying mechanisms may lead to clues for targeted therapy

Ophthalmology Times’ Editorial Advisory Board members share their thoughts on what to watch in year ahead

Ophthalmology benefiting from active programs for innovative product development in 2018 and onward

Orbital and adnexal anatomy and pathology can affect IOP and its measurement as well as planning of glaucoma surgery, and these structures can be affected by medical and surgical treatment of glaucoma

Optical coherence tomography angiography is finding new uses in glaucoma, as it can depict loss of blood vessels around the optic nerve and distinguish vascular layers.

Here's how your practice can utilize Facebook to reach out and spread the word about how you can help people with glaucoma.

The piezo-print microdosing delivers drugs in less than 80 milliseconds, beating the eye’s 100-millisecond reflex.

Results from MERCURY-1, a 12-month phase III pivotal trial, show that once daily treatment with fixed-dose combination netarsudil 0.02%/latanoprost 0.005% (Aerie Pharmaceuticals) is safe and provided significantly greater IOP-lowering than either of its components throughout follow-up.

Know the patient’s family history of glaucoma, and conduct a comprehensive exam before LASIK procedure. It is crucial to monitor the patient after surgery; watch for interfact cysts, loose flaps, and pressure-induced interlamellar stromal keratitis.

Compared with SLT, PSLT appears to offer some advantages, such as a shorter duration of treatment and more comfort for patients.

Steven Vold, MD, reports that toric IOLs provide an accurate, safe, and convenient way to correct astigmatism and uncorrected distance vision for glaucoma patients, while patients wanting presbyopic correction have IOL options to fit a range of visual needs.

Until now, surgery has been considered a second-line treatment after medication and lasers because of the risks associated with trabeculectomy and tube shunts. Now ophthalmologists can draw from a larger surgical tool chest, explains Iqbal Ike K. Ahmed, MD.

Advances in phacoemulsification are creating new opportunities for glaucoma surgery, especially in developing countries, according to Alan S. Crandall, MD.

One laboratory is at work on new devices that use visual stimuli to prompt retinal ganglion cells to regenerate, while two other researchers describe techniques through which virtual reality might diagnose the disease more accurately than standard automated perimetry.

One laboratory is at work on new devices that use visual stimuli to prompt retinal ganglion cells to regenerate, while two other researchers describe techniques through which virtual reality might diagnose the disease more accurately than standard automated perimetry.

In addition to making use of MIGS, interventional glaucoma might utilize other novel drainage devices and sustained drug-delivery devices and be combined with cataract surgery. This approach is more proactive, aims at lower IOP, lowers risk and addresses adherence, said Iqbal Ike K. Ahmed, MD.

Glaucoma 360, a three-day event being held here by the Glaucoma Research Foundation (GRF), will move from its "Celebrate" phase with Annual Gala on Thursday into its "Innovate" phase with the New Horizons Forum set for today. This event is a full day of presentations, panels, and discussions featuring leaders from start-up companies, industry executives, ophthalmic experts, venture capitalists, and the FDA.

Glaucoma 360, a three-day event organized by the Glaucoma Research Foundation (GRF) will move into its final day on Saturday with the Glaucoma Symposium. The focus will shift from "Innovate" to "Educate." Two continuing medical education sessions are-one for ophthalmologists in the morning and another for optometrists in the afternoon.

A portable device for detecting multifocal steady-state visual evoked potentials associated with visual field stimulation is being developed as an objective test for identifying glaucoma-related visual function loss.

A review of glaucoma drugs in various clinical study phases reveals that at least seven new glaucoma drugs were in trials and two others were approved by the FDA in 2017. Many drugs that have progressed the most act on prostaglandin receptors, though some combine this with other mechanisms of action.